Clinical Trials
5 trialsNCT07095452 2026-05-27
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
AbbVie
Phase 2/3 Recruiting
NCT07428369 2026-02-23
LINKER-MM8
Regeneron Pharmaceuticals
Phase 2/3 Not yet recruiting
NCT03759093 2023-09-06
CURATE.AI Optimized Modulation for Multiple Myeloma
National University Hospital, Singapore
Phase 2/3 Unknown
NCT02145598 2019-01-16
GERMAIN
University of Jena
Phase 2/3 Terminated
NCT02419118 2017-11-07
DARA
Vejle Hospital
Phase 2/3 Completed